NASDAQ:UBX

Unity Biotechnology - UBX Stock Forecast, Price & News

$0.43

+0.02 (+4.91%)

(As of 09/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.40
▼
$0.43
50-Day Range: $0.40
▼
$1.37
52-Week Range: $0.39
▼
$3.64

Volume: 891,348 shs
Average Volume: 1.49 million shs
Market Capitalization: $29.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.20

Unity Biotechnology MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,584.6% Upside
$7.20 Price Target
Short Interest: Healthy
2.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.60
Upright™ Environmental Score
News Sentiment: -0.01
Based on 6 Articles This Week
Insider Trading: Selling Shares
$18,821 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.72) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

225th out of 1,096 stocks

Pharmaceutical Preparations Industry

97th out of 548 stocks

3.5

Analyst's Opinion

Consensus Rating
Unity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.20, Unity Biotechnology has a forecasted upside of 1,584.6% from its current price of $0.43.
Amount of Analyst Coverage
Unity Biotechnology has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.11% of the outstanding shares of Unity Biotechnology have been sold short.
Short Interest Ratio / Days to Cover
Unity Biotechnology has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Unity Biotechnology has recently decreased by 16.95%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Unity Biotechnology does not currently pay a dividend.
Dividend Growth
Unity Biotechnology does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Unity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Unity Biotechnology is -0.60.

1.1

News and Social Media Coverage

News Sentiment
Unity Biotechnology has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Unity Biotechnology this week, compared to 1 article on an average week.
Search Interest
Only 18 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
Only 19 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,821.00 in company stock.
Percentage Held by Insiders
Only 3.60% of the stock of Unity Biotechnology is held by insiders.
Percentage Held by Institutions
Only 13.51% of the stock of Unity Biotechnology is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($0.72) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unity Biotechnology is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unity Biotechnology is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Unity Biotechnology has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

September 24, 2022 | americanbankingnews.com

FY2026 EPS Estimates for Unity Biotechnology, Inc. Reduced by Wedbush (NASDAQ:UBX)

September 24, 2022 | reuters.com

UNITY Biotechnology Inc

September 19, 2022 | finance.yahoo.com

UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration

August 31, 2022 | finance.yahoo.com

UNITY Biotechnology to Participate in Upcoming Investor Conferences

August 30, 2022 | finance.yahoo.com

Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now

August 18, 2022 | benzinga.com

Thinking about buying stock in Bed Bath & Beyond, Plug Power, Unity Biotechnology, Eargo, or FuboTV?

August 18, 2022 | finance.yahoo.com

UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering

August 17, 2022 | marketwatch.com

Thinking about buying stock in Plus Therapeutics, Unity Biotechnology, PlayAGS, Torrid, or Bed Bath & Beyond?

August 16, 2022 | finance.yahoo.com

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

August 15, 2022 | msn.com

Analyzing Unity Biotechnology's Short Interest

August 15, 2022 | seekingalpha.com

Unity extends gains on data for lead asset in diabetic macular edema

August 12, 2022 | msn.com

UNITY Biotechnology Shares Rally After Positive Results From Mid-Stage Age-related Eye Disease Study

August 12, 2022 | finance.yahoo.com

UNITY Biotech Shares More Than Double On Positive Drug Data For Diabetes Associated Vision Loss

August 12, 2022 | investorplace.com

Why Is Unity Biotechnology (UBX) Stock Up 71% Today?

August 12, 2022 | investing.com

Pre-Open Movers: Small-cap UNITY Bio Climbs 110%, Alibaba Declines

August 12, 2022 | nasdaq.com

UNITY Reports Positive Proof-of-concept Data With UBX1325 In Patients With Diabetic Macular Edema

August 12, 2022 | finance.yahoo.com

UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates

August 12, 2022 | seekingalpha.com

Unity Biotech jumps 93% after data for lead asset in diabetic macular edema

August 12, 2022 | finance.yahoo.com

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

August 12, 2022 | finance.yahoo.com

UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates

August 11, 2022 | finance.yahoo.com

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

August 5, 2022 | nasdaq.com

Unity Biotechnology (NASDAQ:UBX) adds US$4.8m to market cap in the past 7 days, though investors from three years ago are still down 90%

July 12, 2022 | finance.yahoo.com

UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

May 26, 2022 | finance.yahoo.com

UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

May 10, 2022 | finance.yahoo.com

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Company Calendar

Last Earnings: 8/12/2022
Today: 9/29/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:UBX
CUSIP: N/A
CIK: 1463361
Web: www.unitybiotechnology.com
Phone: (650) 416-1192
Fax: N/A
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.20
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +1,584.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-60,720,000.00
Net Margins: N/A
Pretax Margin: -1,179.18%
Return on Equity: -113.88%
Return on Assets: -51.42%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 4.13
Quick Ratio: 4.13

Sales & Book Value

Annual Sales: $4.78 million
Price / Sales: 6.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.03 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 69,650,000
Free Float: 67,144,000
Market Cap: $29.77 million
Optionable: Not Optionable
Beta: 0.73

Key Executives

Dr. Anirvan Ghosh Ph.D. (Age 58)
CEO & Director
Comp: $885.54k

Dr. Nathaniel E. David A.B. (Age 54)
Ph.D., Co-Founder & Exec. Director
Comp: $40k

Ms. Lynne Marie Sullivan (Age 55)
CFO & Head of Corp. Devel.
Comp: $614.84k

Dr. Jamie Dananberg M.D. (Age 64)
Chief Medical Officer
Comp: $635.79k

Dr. Jan M. van Deursen
Founder

Dr. Judith Campisi Ph.D.
Founder

Mr. Daohong Zhou M.D.
Founder

Mr. Nathan Guz Ph.D.
VP of Operations

Mr. Alexander Azoy (Age 46)
VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer

Dr. Przemyslaw Sapieha Ph.D.
Chief Scientific Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

UBX Stock - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UBX shares.
View UBX analyst ratings or view top-rated stocks.
What is Unity Biotechnology's stock price forecast for 2022?: 6 Wall Street analysts have issued 12-month price targets for Unity Biotechnology's stock. Their UBX share price forecasts range from $4.00 to $12.00. On average, they expect the company's share price to reach $7.20 in the next twelve months. This suggests a possible upside of 1,584.6% from the stock's current price.
View analysts price targets for UBX or view top-rated stocks among Wall Street analysts.
How have UBX shares performed in 2022?: Unity Biotechnology's stock was trading at $1.46 on January 1st, 2022. Since then, UBX stock has decreased by 70.7% and is now trading at $0.4274.
View the best growth stocks for 2022 here.
When is Unity Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our UBX earnings forecast.
How were Unity Biotechnology's earnings last quarter?: Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.09. The firm had revenue of $0.24 million for the quarter.
What other stocks do shareholders of Unity Biotechnology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?: (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.
What is Unity Biotechnology's stock symbol?: Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."
Who are Unity Biotechnology's major shareholders?: Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.38%), FMR LLC (1.35%), Millennium Management LLC (0.48%), State Street Corp (0.19%), Franklin Resources Inc. (0.09%) and Virtu Financial LLC (0.09%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends.
How do I buy shares of Unity Biotechnology?: Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Unity Biotechnology's stock price today?: One share of UBX stock can currently be purchased for approximately $0.43.
How much money does Unity Biotechnology make?: Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $29.77 million and generates $4.78 million in revenue each year. The company earns $-60,720,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.
How can I contact Unity Biotechnology?: The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.

This page (NASDAQ:UBX) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Unity Biotechnology - UBX Stock Forecast, Price & News

Unity Biotechnology MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Unity Biotechnology (NASDAQ:UBX) Stock

UBX Stock News Headlines

UBX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

UBX Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™